Waters Corporation has beaten earnings estimates in all 4 of the last 4 quarters and posted exceptional revenue growth of 91% year-over-year, but negative price momentum with a falling on-balance-volume and a cash flow red flag — free cash flow was -112% of net income — create meaningful fundamental concerns.
Thesis pillars
- Perfect Earnings Beat Revenue Surge↓Deteriorating
- Free Cash Flow Quality Red Flag↓Deteriorating
- Negative Momentum Falling Obv↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Waters Corporation (WAT) Stock Analysis
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $412.17, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.9% away).
Waters Corporation manufactures liquid chromatography, mass spectrometry, and thermal analysis instruments for pharmaceutical, life science, and industrial markets, with approximately 69% of 2025 net sales outside the United States. Revenue comes from instrument systems,... Read more
Hold if already holding. Not a fresh buy at $412.17, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.9% away). Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Waters Corporation
About Waters Corporation
Waters Corporation sourced approximately 69% of its 2025 net sales from outside the United States, serving pharmaceutical, life science, environmental, and industrial customers with liquid chromatography, mass spectrometry, and thermal analysis instrumentation developed over more than 65 years. The company closed the $16.8 billion BDS Business acquisition from Becton, Dickinson on February 9, 2026, reorganizing into four segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. Prior to that transaction, two operating segments — Waters LC/MS and TA Instruments — were aggregated into a single reporting segment for financial purposes.
Waters earns revenue across three product lines that customers frequently use together: LC instrument systems and the chromatography columns they consume (replaced at regular intervals by quality-control laboratories to maintain separation accuracy), MS instrument systems used in drug discovery and clinical diagnostics, and TA thermal analysis and rheometry instruments. The pharmaceutical and life science industries represent the primary end markets, with LC mandated by the FDA, EPA, and their international counterparts for safety and efficacy testing across drug development, nutritional safety, and environmental monitoring. Manufacturing is concentrated in Ireland and the United Kingdom, with key subcontractors in Singapore handling portions of production and support services. The BDS Business adds BD's former specimen collection products, infectious disease and cancer diagnostics reagent systems, and flow cytometry tools for immunology and oncology research — materially broadening end-market exposure beyond analytical instruments.
Show full overview
Waters' 69% international revenue share exposes the company to foreign currency movements, geopolitical disruptions, and government procurement policy shifts. China is the most explicitly flagged single-market risk: net sales there fell 10% in 2024 due to declining economic conditions, trade tensions, Chinese government tightening on procurement by state-funded customers, and increased local competition — before recovering 10% in 2025. Manufacturing in Ireland and the United Kingdom, combined with Singapore subcontractors, concentrates production in non-U.S. jurisdictions subject to their own regulatory and currency risks. The $4.0 billion of BDS Acquisition indebtedness assumed — a $3.5 billion tranche maturing February 2027 and a $500 million tranche maturing February 2028 — adds a refinancing risk layer to the internationally concentrated cost structure.
See also: Healthcare · Diagnostics & Research
From Waters Corporation's most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-08-16Recent Developments — Waters Corporation
Latest news
- NEWS Waters Corp. stock underperforms Wednesday when compared to competitors - MarketWatch — MarketWatch negative
- NEWS Waters Corp. stock underperforms Wednesday when compared to competitors - marketwatch.com — marketwatch.com negative
- NEWS WAT|Waters Corp|Price:371.191|Chg%:-8.289 - TradingKey — TradingKey negative
- NEWS Waters Corporation stock (US9418481035): Stable demand after recent earnings update - AD HOC NEWS — AD HOC NEWS positive
- NEWS Waters Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch — MarketWatch negative
Generated 2026-08-16T12:27:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $412.17, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.9% away). Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Target $474.00 (+15.0%), stop $387.15 (−6.5%), A.R:R -0.3:1. Score 5.9/10, moderate confidence.
Take-profit target: $474.00 (-4.8% upside). Target $474.00 (+15.0%), stop $387.15 (−6.5%), A.R:R -0.3:1. Stop-loss: $387.15.
Analyst target reached - limited upside remaining; Near 52-week high (1.9% away); Euphoria warning: extreme positivity (+1.00) + overbought RSI 79.
Waters Corporation trades at a P/E of 103.8 (forward 24.9). TrendMatrix value score: 3.3/10. Verdict: Hold.
31 analysts cover WAT with a consensus score of 3.8/5. Average price target: $436.
What does Waters Corporation do?Waters Corporation manufactures liquid chromatography, mass spectrometry, and thermal analysis instruments for...
Waters Corporation manufactures liquid chromatography, mass spectrometry, and thermal analysis instruments for pharmaceutical, life science, and industrial markets, with approximately 69% of 2025 net sales outside the United States. Revenue comes from instrument systems, consumable columns replaced at regular intervals, and post-warranty service plans; the company closed the $16.8 billion BDS Business acquisition from Becton, Dickinson in February 2026, adding diagnostics and biosciences segments.